Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/17/2025 | $72.00 | Buy | Citigroup |
| 12/6/2024 | $47.00 | Neutral | Goldman |
| 12/6/2024 | $62.00 | Outperform | BMO Capital Markets |
| 11/5/2024 | $58.00 | Outperform | Wedbush |
| 9/24/2024 | $65.00 | Buy | TD Cowen |
| 9/9/2024 | $60.00 | Buy | Truist |
| 10/30/2023 | $32.00 | Overweight | CapitalOne |
| 5/25/2023 | $30.00 → $40.00 | Buy | Jefferies |
SCHEDULE 13G - Protagonist Therapeutics, Inc (0001377121) (Subject)
SCHEDULE 13G - Protagonist Therapeutics, Inc (0001377121) (Subject)
10-Q - Protagonist Therapeutics, Inc (0001377121) (Filer)
Citigroup initiated coverage of Protagonist Therapeutics with a rating of Buy and set a new price target of $72.00
Goldman initiated coverage of Protagonist Therapeutics with a rating of Neutral and set a new price target of $47.00
BMO Capital Markets initiated coverage of Protagonist Therapeutics with a rating of Outperform and set a new price target of $62.00